Emraclidine vs NTX-253

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Muscarinic M4 receptor · full Schizophrenia pipeline

Emraclidine

Developed by AbbVie and partners

Phase 2 in Schizophreniasmall molecule
Partial signal

NCT05227703 · Phase 2 · completed

Participants were randomly assigned to emraclidine 15 mg, emraclidine 30 mg, or matching placebo and were double-blinded, with 130–131 participants per group. The primary clinical endpoint was not met: the Week 6 PANSS comparison was nonsignificant for both 15 mg versus placebo (p=0.2925) and 30 mg versus placebo (p=0.3914).

Next expected readout: February 2028 · NCT07145918 (registry estimate)

Reported efficacy

Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) (missed)

Result source: NCT05227703

NTX-253

Developed by Neurosterix Pharma Sàrl

Phase 1 in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmraclidineNTX-253
PANSS total, change-14.2 vs -16.1+1.9 vs placebo30mg QD · wk 6 · n 96NCT05227703
27 other results
  • -16.5 vs -13.5 30 mg once daily · wk 6 · n 93 · Phase 2 · primary NCT05227690
  • -18.5 vs -16.1 15mg QD · wk 6 · n 94 · Phase 2 · primary NCT05227703
  • -14.7 vs -13.5 10 mg once daily · wk 6 · n 90 · Phase 2 · primary NCT05227690
  • -14.2 vs -16.1 30 mg QD · wk 6 · n 123 · Phase 2 · secondary NCT05227703
  • -16.5 vs -13.5 30 mg once daily · wk 6 · n 127 · Phase 2 · secondary NCT05227690
  • -12.9 vs -14.7 30 mg QD · wk 5 · n 123 · Phase 2 · secondary NCT05227703
  • -14.7 vs -13.2 30 mg once daily · wk 5 · n 127 · Phase 2 · secondary NCT05227690
  • -12 vs -12.8 30 mg QD · wk 4 · n 123 · Phase 2 · secondary NCT05227703
  • -13.3 vs -12.1 30 mg once daily · wk 4 · n 127 · Phase 2 · secondary NCT05227690
  • -10 vs -11.2 30 mg QD · wk 3 · n 123 · Phase 2 · secondary NCT05227703
  • -11.3 vs -10.3 30 mg once daily · wk 3 · n 127 · Phase 2 · secondary NCT05227690
  • -7.5 vs -8.5 30 mg QD · wk 2 · n 123 · Phase 2 · secondary NCT05227703
  • -9 vs -8.7 30 mg once daily · wk 2 · n 127 · Phase 2 · secondary NCT05227690
  • -4.9 vs -5 30 mg QD · wk 1 · n 123 · Phase 2 · secondary NCT05227703
  • -6.2 vs -5.2 30 mg once daily · wk 1 · n 127 · Phase 2 · secondary NCT05227690
  • -18.5 vs -16.1 15 mg QD · wk 6 · n 122 · Phase 2 · secondary NCT05227703
  • -16.5 vs -14.7 15 mg QD · wk 5 · n 122 · Phase 2 · secondary NCT05227703
  • -13.4 vs -12.8 15 mg QD · wk 4 · n 122 · Phase 2 · secondary NCT05227703
  • -12.5 vs -11.2 15 mg QD · wk 3 · n 122 · Phase 2 · secondary NCT05227703
  • -8.7 vs -8.5 15 mg QD · wk 2 · n 122 · Phase 2 · secondary NCT05227703
  • -6.8 vs -5 15 mg QD · wk 1 · n 122 · Phase 2 · secondary NCT05227703
  • -14.7 vs -13.5 10 mg once daily · wk 6 · n 124 · Phase 2 · secondary NCT05227690
  • -14 vs -13.2 10 mg once daily · wk 5 · n 124 · Phase 2 · secondary NCT05227690
  • -12.8 vs -12.1 10 mg once daily · wk 4 · n 124 · Phase 2 · secondary NCT05227690
  • -10 vs -10.3 10 mg once daily · wk 3 · n 124 · Phase 2 · secondary NCT05227690
  • -8.8 vs -8.7 10 mg once daily · wk 2 · n 124 · Phase 2 · secondary NCT05227690
  • -5.7 vs -5.2 10 mg once daily · wk 1 · n 124 · Phase 2 · secondary NCT05227690
—Not reported
CGI-S, change-0.8 vs -0.8±0 vs placebo30 mg QD · wk 6 · n 96NCT05227703
27 other results
  • -0.8 vs -0.8 30 mg QD · wk 6 · n 123 · Phase 2 · secondary NCT05227703
  • -0.8 vs -0.7 30 mg once daily · wk 6 · n 93 · Phase 2 · secondary NCT05227690
  • -0.8 vs -0.7 30 mg once daily · wk 6 · n 127 · Phase 2 · secondary NCT05227690
  • -0.7 vs -0.8 30 mg QD · wk 5 · n 123 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.7 30 mg once daily · wk 5 · n 127 · Phase 2 · secondary NCT05227690
  • -0.6 vs -0.7 30 mg QD · wk 4 · n 123 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.5 30 mg once daily · wk 4 · n 127 · Phase 2 · secondary NCT05227690
  • -0.5 vs -0.6 30 mg QD · wk 3 · n 123 · Phase 2 · secondary NCT05227703
  • -0.5 vs -0.5 30 mg once daily · wk 3 · n 127 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.4 30 mg QD · wk 2 · n 123 · Phase 2 · secondary NCT05227703
  • -0.3 vs -0.4 30 mg once daily · wk 2 · n 127 · Phase 2 · secondary NCT05227690
  • -0.2 vs -0.2 30 mg QD · wk 1 · n 123 · Phase 2 · secondary NCT05227703
  • -0.2 vs -0.2 30 mg once daily · wk 1 · n 127 · Phase 2 · secondary NCT05227690
  • -1.1 vs -0.8 15 mg QD · wk 6 · n 94 · Phase 2 · secondary NCT05227703
  • -1.1 vs -0.8 15 mg QD · wk 6 · n 122 · Phase 2 · secondary NCT05227703
  • -0.9 vs -0.8 15 mg QD · wk 5 · n 122 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.7 15 mg QD · wk 4 · n 122 · Phase 2 · secondary NCT05227703
  • -0.6 vs -0.6 15 mg QD · wk 3 · n 122 · Phase 2 · secondary NCT05227703
  • -0.4 vs -0.4 15 mg QD · wk 2 · n 122 · Phase 2 · secondary NCT05227703
  • -0.3 vs -0.2 15 mg QD · wk 1 · n 122 · Phase 2 · secondary NCT05227703
  • -0.8 vs -0.7 10 mg once daily · wk 6 · n 90 · Phase 2 · secondary NCT05227690
  • -0.8 vs -0.7 10 mg once daily · wk 6 · n 124 · Phase 2 · secondary NCT05227690
  • -0.6 vs -0.7 10 mg once daily · wk 5 · n 124 · Phase 2 · secondary NCT05227690
  • -0.5 vs -0.5 10 mg once daily · wk 4 · n 124 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.5 10 mg once daily · wk 3 · n 124 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.4 10 mg once daily · wk 2 · n 124 · Phase 2 · secondary NCT05227690
  • -0.2 vs -0.2 10 mg once daily · wk 1 · n 124 · Phase 2 · secondary NCT05227690
—Not reported
PANSS response—Not reported—Not reported
PSP, change—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

PANSS total, change

Emraclidine
-14.2 vs -16.1+1.9 vs placebo30mg QD · wk 6 · n 96NCT05227703
27 other results
  • -16.5 vs -13.5 30 mg once daily · wk 6 · n 93 · Phase 2 · primary NCT05227690
  • -18.5 vs -16.1 15mg QD · wk 6 · n 94 · Phase 2 · primary NCT05227703
  • -14.7 vs -13.5 10 mg once daily · wk 6 · n 90 · Phase 2 · primary NCT05227690
  • -14.2 vs -16.1 30 mg QD · wk 6 · n 123 · Phase 2 · secondary NCT05227703
  • -16.5 vs -13.5 30 mg once daily · wk 6 · n 127 · Phase 2 · secondary NCT05227690
  • -12.9 vs -14.7 30 mg QD · wk 5 · n 123 · Phase 2 · secondary NCT05227703
  • -14.7 vs -13.2 30 mg once daily · wk 5 · n 127 · Phase 2 · secondary NCT05227690
  • -12 vs -12.8 30 mg QD · wk 4 · n 123 · Phase 2 · secondary NCT05227703
  • -13.3 vs -12.1 30 mg once daily · wk 4 · n 127 · Phase 2 · secondary NCT05227690
  • -10 vs -11.2 30 mg QD · wk 3 · n 123 · Phase 2 · secondary NCT05227703
  • -11.3 vs -10.3 30 mg once daily · wk 3 · n 127 · Phase 2 · secondary NCT05227690
  • -7.5 vs -8.5 30 mg QD · wk 2 · n 123 · Phase 2 · secondary NCT05227703
  • -9 vs -8.7 30 mg once daily · wk 2 · n 127 · Phase 2 · secondary NCT05227690
  • -4.9 vs -5 30 mg QD · wk 1 · n 123 · Phase 2 · secondary NCT05227703
  • -6.2 vs -5.2 30 mg once daily · wk 1 · n 127 · Phase 2 · secondary NCT05227690
  • -18.5 vs -16.1 15 mg QD · wk 6 · n 122 · Phase 2 · secondary NCT05227703
  • -16.5 vs -14.7 15 mg QD · wk 5 · n 122 · Phase 2 · secondary NCT05227703
  • -13.4 vs -12.8 15 mg QD · wk 4 · n 122 · Phase 2 · secondary NCT05227703
  • -12.5 vs -11.2 15 mg QD · wk 3 · n 122 · Phase 2 · secondary NCT05227703
  • -8.7 vs -8.5 15 mg QD · wk 2 · n 122 · Phase 2 · secondary NCT05227703
  • -6.8 vs -5 15 mg QD · wk 1 · n 122 · Phase 2 · secondary NCT05227703
  • -14.7 vs -13.5 10 mg once daily · wk 6 · n 124 · Phase 2 · secondary NCT05227690
  • -14 vs -13.2 10 mg once daily · wk 5 · n 124 · Phase 2 · secondary NCT05227690
  • -12.8 vs -12.1 10 mg once daily · wk 4 · n 124 · Phase 2 · secondary NCT05227690
  • -10 vs -10.3 10 mg once daily · wk 3 · n 124 · Phase 2 · secondary NCT05227690
  • -8.8 vs -8.7 10 mg once daily · wk 2 · n 124 · Phase 2 · secondary NCT05227690
  • -5.7 vs -5.2 10 mg once daily · wk 1 · n 124 · Phase 2 · secondary NCT05227690
NTX-253
—Not reported

CGI-S, change

Emraclidine
-0.8 vs -0.8±0 vs placebo30 mg QD · wk 6 · n 96NCT05227703
27 other results
  • -0.8 vs -0.8 30 mg QD · wk 6 · n 123 · Phase 2 · secondary NCT05227703
  • -0.8 vs -0.7 30 mg once daily · wk 6 · n 93 · Phase 2 · secondary NCT05227690
  • -0.8 vs -0.7 30 mg once daily · wk 6 · n 127 · Phase 2 · secondary NCT05227690
  • -0.7 vs -0.8 30 mg QD · wk 5 · n 123 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.7 30 mg once daily · wk 5 · n 127 · Phase 2 · secondary NCT05227690
  • -0.6 vs -0.7 30 mg QD · wk 4 · n 123 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.5 30 mg once daily · wk 4 · n 127 · Phase 2 · secondary NCT05227690
  • -0.5 vs -0.6 30 mg QD · wk 3 · n 123 · Phase 2 · secondary NCT05227703
  • -0.5 vs -0.5 30 mg once daily · wk 3 · n 127 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.4 30 mg QD · wk 2 · n 123 · Phase 2 · secondary NCT05227703
  • -0.3 vs -0.4 30 mg once daily · wk 2 · n 127 · Phase 2 · secondary NCT05227690
  • -0.2 vs -0.2 30 mg QD · wk 1 · n 123 · Phase 2 · secondary NCT05227703
  • -0.2 vs -0.2 30 mg once daily · wk 1 · n 127 · Phase 2 · secondary NCT05227690
  • -1.1 vs -0.8 15 mg QD · wk 6 · n 94 · Phase 2 · secondary NCT05227703
  • -1.1 vs -0.8 15 mg QD · wk 6 · n 122 · Phase 2 · secondary NCT05227703
  • -0.9 vs -0.8 15 mg QD · wk 5 · n 122 · Phase 2 · secondary NCT05227703
  • -0.7 vs -0.7 15 mg QD · wk 4 · n 122 · Phase 2 · secondary NCT05227703
  • -0.6 vs -0.6 15 mg QD · wk 3 · n 122 · Phase 2 · secondary NCT05227703
  • -0.4 vs -0.4 15 mg QD · wk 2 · n 122 · Phase 2 · secondary NCT05227703
  • -0.3 vs -0.2 15 mg QD · wk 1 · n 122 · Phase 2 · secondary NCT05227703
  • -0.8 vs -0.7 10 mg once daily · wk 6 · n 90 · Phase 2 · secondary NCT05227690
  • -0.8 vs -0.7 10 mg once daily · wk 6 · n 124 · Phase 2 · secondary NCT05227690
  • -0.6 vs -0.7 10 mg once daily · wk 5 · n 124 · Phase 2 · secondary NCT05227690
  • -0.5 vs -0.5 10 mg once daily · wk 4 · n 124 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.5 10 mg once daily · wk 3 · n 124 · Phase 2 · secondary NCT05227690
  • -0.4 vs -0.4 10 mg once daily · wk 2 · n 124 · Phase 2 · secondary NCT05227690
  • -0.2 vs -0.2 10 mg once daily · wk 1 · n 124 · Phase 2 · secondary NCT05227690
NTX-253
—Not reported

PANSS response

Emraclidine
—Not reported
NTX-253
—Not reported

PSP, change

Emraclidine
—Not reported
NTX-253
—Not reported

Relapse (% of patients)

Emraclidine
—Not reported
NTX-253
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NTX-253: no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Emraclidine: 4 of 4 rows · NTX-253: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmraclidine
Dropout rate
29%30 mg QDa
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 5 more results
—30mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
28.5%15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
—15mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
28.7%30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
30.5%10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.1%30 mg QDa
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 5 more results
—30mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
4.6%15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
—15mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
7.8%30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
4.7%10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
Serious AEs
—30 mg QDa
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 5 more results
0.8%30mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
—15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
2.3%15mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
0.8%30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
3.1%10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
30mg QDa
headache 13% (placebo 10.8%)
dry mouth 5.3% (placebo 0.8%)
anxiety 3.1% (placebo 3.1%)
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 3 more results
15mg QD
headache 13.8% (placebo 10.8%)
weight increased 8.5% (placebo 3.8%)
constipation 4.6% (placebo 1.5%)
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
30 mg once daily
headache 13.2% (placebo 9.4%)
dry mouth 9.3% (placebo 2.3%)
dyspepsia 7.8% (placebo 3.1%)
NCT05227690 · Phase 2 · registry result, not featured evidence
10 mg once daily
weight increased 17.2% (placebo 8.6%)
headache 14.1% (placebo 9.4%)
somnolence 7% (placebo 4.7%)
NCT05227690 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Emraclidine

PANSS Total -14.2 vs -16.1 placebo score @ 6wk30mg QD
absolute change · score
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 27 more results
-4.9 vs -5 placebo score @ 1wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-7.5 vs -8.5 placebo score @ 2wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-10 vs -11.2 placebo score @ 3wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-12 vs -12.8 placebo score @ 4wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-12.9 vs -14.7 placebo score @ 5wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-14.2 vs -16.1 placebo score @ 6wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-16.5 vs -13.5 placebo score @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-6.2 vs -5.2 placebo score @ 1wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-9 vs -8.7 placebo score @ 2wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-11.3 vs -10.3 placebo score @ 3wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-13.3 vs -12.1 placebo score @ 4wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-14.7 vs -13.2 placebo score @ 5wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-16.5 vs -13.5 placebo score @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-18.5 vs -16.1 placebo score @ 6wk15mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-6.8 vs -5 placebo score @ 1wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-8.7 vs -8.5 placebo score @ 2wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-12.5 vs -11.2 placebo score @ 3wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-13.4 vs -12.8 placebo score @ 4wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-16.5 vs -14.7 placebo score @ 5wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-18.5 vs -16.1 placebo score @ 6wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-14.7 vs -13.5 placebo score @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-5.7 vs -5.2 placebo score @ 1wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-8.8 vs -8.7 placebo score @ 2wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-10 vs -10.3 placebo score @ 3wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-12.8 vs -12.1 placebo score @ 4wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-14 vs -13.2 placebo score @ 5wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-14.7 vs -13.5 placebo score @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
CGI-S -0.8 vs -0.83 placebo score @ 6wk30 mg QD
absolute change · score
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 27 more results
-0.21 vs -0.21 placebo score @ 1wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.38 vs -0.42 placebo score @ 2wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.49 vs -0.55 placebo score @ 3wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.62 vs -0.72 placebo score @ 4wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.69 vs -0.78 placebo score @ 5wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.8 vs -0.83 placebo score @ 6wk30 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.84 vs -0.7 placebo score @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.21 vs -0.18 placebo score @ 1wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.35 vs -0.36 placebo score @ 2wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.52 vs -0.48 placebo score @ 3wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.7 vs -0.54 placebo score @ 4wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.74 vs -0.67 placebo score @ 5wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.84 vs -0.7 placebo score @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-1.05 vs -0.83 placebo score @ 6wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.33 vs -0.21 placebo score @ 1wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.42 vs -0.42 placebo score @ 2wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.64 vs -0.55 placebo score @ 3wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.74 vs -0.72 placebo score @ 4wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.91 vs -0.78 placebo score @ 5wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-1.05 vs -0.83 placebo score @ 6wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
-0.75 vs -0.7 placebo score @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.17 vs -0.18 placebo score @ 1wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.39 vs -0.36 placebo score @ 2wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.42 vs -0.48 placebo score @ 3wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.53 vs -0.54 placebo score @ 4wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.64 vs -0.67 placebo score @ 5wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
-0.75 vs -0.7 placebo score @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
PANSS 30% 12.2% (n=123) vs 19.5% (n=128) placebo @ 6wk30 mg QD
responder rate · % of participants
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
show 3 more results
17.3% (n=127) vs 10.2% (n=127) placebo @ 6wk30 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence
23.8% (n=122) vs 19.5% (n=128) placebo @ 6wk15 mg QD
NCT05227703 · Phase 2 · monotherapy · Schizophrenia · phase 2
17.6% (n=125) vs 10.2% (n=127) placebo @ 6wk10 mg once daily
NCT05227690 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emraclidine's landscape · NTX-253's landscape